| P50 | author | Diether Lambrechts | Q26923514 |
| | Frédéric Amant | Q90141632 |
| P2093 | author name string | Lieve Coenegrachts | |
| | Els Hermans | |
| | Jeroen Depreeuw | |
| | Stefanie Schrauwen | |
| P2860 | cites work | The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation | Q24616946 |
| | Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor | Q40164535 |
| | A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors | Q41699326 |
| | Microsatellite instable and microsatellite stable primary endometrial carcinoma cells and their subcutaneous and orthotopic xenografts recapitulate the characteristics of the corresponding primary tumor | Q52965839 |
| | Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer | Q54375657 |
| | The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer | Q54535188 |
| | Endometrial cancer | Q63199203 |
| | Hormonal treatment of endometrial cancer | Q73193725 |
| | Endometrial cancer | Q84603998 |
| | Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 Has a Therapeutic Potential and Sensitizes Cisplatin in Nasopharyngeal Carcinoma | Q27332333 |
| | Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor | Q27676347 |
| | Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer | Q27852608 |
| | Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial | Q27853021 |
| | Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. | Q27853084 |
| | Cancer statistics, 2014 | Q27861018 |
| | Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma | Q28472048 |
| | Establishment, characterization and chemosensitivity of three mismatch repair deficient cell lines from sporadic and inherited colorectal carcinomas | Q28484668 |
| | Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies | Q29616780 |
| | Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity | Q29618117 |
| | NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells | Q34000632 |
| | Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas | Q34291001 |
| | PI3K inhibitors for cancer treatment: where do we stand? | Q34921551 |
| | Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models | Q35018805 |
| | Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group | Q35172203 |
| | Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. | Q36675804 |
| | Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO. | Q36857470 |
| | Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions | Q37209222 |
| | Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. | Q37596249 |
| | Markers for individualised therapy in endometrial carcinoma | Q38030768 |
| | Selumetinib in advanced non small cell lung cancer (NSCLC) harbouring KRAS mutation: endless clinical challenge to KRAS-mutant NSCLC. | Q38142260 |
| | Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors | Q38406496 |
| | PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways | Q38951260 |
| | The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma | Q38985133 |
| | Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3‐kinase inhibitor BEZ235 and the PI3‐kinase inhibitor BKM120 in hepatocellular carcinoma | Q39181242 |
| | Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors | Q39226360 |
| | Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ- and GNA11-Dependent Manner | Q39325158 |
| | Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake | Q39516398 |
| | AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl | Q40093939 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endometrial carcinoma | Q18555222 |
| | xenograft | Q64148587 |
| P304 | page(s) | 165-173 | |
| P577 | publication date | 2015-04-28 | |
| P1433 | published in | Gynecologic Oncology | Q5625182 |
| P1476 | title | Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models | |
| P478 | volume | 138 | |